Know Cancer

forgot password

Preventing Adverse Drug Events With PatientSite

18 Years
Not Enrolling
Adverse Drug Event

Thank you

Trial Information

Preventing Adverse Drug Events With PatientSite

- A drug safety module called MedCheck was developed for PatientSite. This allows
physicians to query patients automatically 10 days after they receive a new
prescription asking them questions about their new prescription. In this study new
enhancements will be tested.

- Participants will be assigned at random to the intervention group or control group.
The intervention group will receive a single electronic PatientSite message asking them
questions about the new prescription which is then forwarded to their physician. The
control group will receive a generic message about medication safety.

- To identify adverse drug events, a telephone survey and medical record review will be
conducted of patients in the intervention group and controls.

- This study will run for 12 months.

Inclusion Criteria:

- Adult patients >18

- Patients that receive a new prescription

- Proficient in spoken and written english

Exclusion Criteria:

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Outcome Measure:

To prevent adverse drug events with PatientSite.

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Saul N Weingart, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Institutional Review Board

Study ID:




Start Date:

April 2003

Completion Date:

December 2004

Related Keywords:

  • Adverse Drug Event
  • Adverse drug event
  • Patient safety
  • Internet portal
  • PatientSite
  • Preventive health
  • Primary care
  • Drug Toxicity



Beth Israel Deaconess Medical Center Boston, Massachusetts  02215